Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?

Pediatric Critical Care Medicine

Volumn 10, Issue 5, 2009, Pages 572-582

  Warren, Oliver J ^a   Rogers, Paula L B ^a   Watret, Amy L ^a   De Wit, Katie L ^a   Darzi, Ara W ^a   Gill, Ravi ^b   Athanasiou, Thanos ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiac surgical procedures; Cardiopulmonary bypass; Hemorrhage; Pediatrics; Recombinantfactor VIIa; Treatment outcome

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD CLOTTING TEST; CONGENITAL BLOOD CLOTTING DISORDER; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; HEART SURGERY; HEMODILUTION; HEMOPHILIA; HUMAN; LITERATURE; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SAFETY; PEDIATRIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; SURGICAL MORTALITY; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; TUBE;

CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; HUMANS; PEDIATRICS; POSTOPERATIVE HEMORRHAGE;

EID: 70349964749     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181a642d5     Document Type: Article

References (82)

1. Chambers LA, Cohen DM, Davis JT: Transfusion patterns in pediatric open heart surgery. Transfusion 1996; 36:150-154 (Pubitemid 26070879)
2. Petaja J, Lundstrom U, Leijala M, et al: Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg 1995; 109:524-529
3. Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: A review. Intensive Care Med 2004; 30: 1873-1881 (Pubitemid 39468407)
4. McEwan A: Aspects of bleeding after cardiac surgery in children. Paediatr Anaesth 2007; 17:1126-1133 (Pubitemid 350059099)
5. Kern FH, Morana NJ, Sears JJ, et al: Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 541-546
6. Andrew M, Vegh P, Johnston M, et al: Maturation of the hemostatic system during childhood. Blood 1992; 80:1998-2005
7. Michelson AD: Platelet function in the newborn. Semin Thromb Hemost 1998; 24: 507-512
8. Rajasekhar D, Barnard MR, Bednarek FJ, et al: Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost 1997; 77: 1002-1007 (Pubitemid 27239130)
9. Lippi G, Franchini M, Montagnana M, et al: Coagulation testing in pediatric patients: The young are not just miniature adults. Semin Thromb Hemost 2007; 33:816-820 (Pubitemid 351158450)
10. Monagle P, Michelson AD, Bovill E, et al: Antithrombotic therapy in children. Chest 2001; 119:344S-370S (Pubitemid 32154210)
11. Guzzetta NA, Miller BE, Todd K, et al: An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg 2005; 100:1276-1282, table of contents (Pubitemid 40577369)
12. Odegard KC, Zurakowski D, Hornykewycz S, et al: Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg 2007; 83: 1797-1803 (Pubitemid 46616780)
13. Stanworth SJ, Bennett C: How to tackle bleeding and thrombosis in the newborn. Early Hum Dev 2008; 84:507-513
14. Guay J: Invited commentary. Ann Thorac Surg 2007; 83:1803-1804 (Pubitemid 46616796)
15. Lippi G, Salvagno GL, Rugolotto S, et al: Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis 2007; 24:153-155
16. Richardson MW, Allen GA, Monahan PE: Thrombosis in children: Current perspective and distinct challenges. Thromb Haemost 2002; 88:900-911
17. Williams GD, Bratton SL, Ramamoorthy C: Factors associated with blood loss and blood product transfusions: A multivariate analysis in children after open-heart surgery. Anesth Analg 1999; 89:57-64
18. Williams GD, Bratton SL, Riley EC, et al: Association between age and blood loss in children undergoing open heart operations. Ann Thorac Surg 1998; 66:870-875; discussion 875-876
19. Miller BE, Mochizuki T, Levy JH, et al: Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997; 85:1196-1202 (Pubitemid 28130510)
20. Chan AK, Leaker M, Burrows FA, et al: Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77:270-277 (Pubitemid 27084914)
21. Henriksson P, Varendh G, Lundstrom NR: Haemostatic defects in cyanotic congenital heart disease. Br Heart J 1979; 41:23-27 (Pubitemid 9106741)
22. Tempe DK, Virmani S: Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth 2002; 16:752-765 (Pubitemid 36076468)
23. http://www.fda.gov/cber/products/novoseven. htm. Accessed May 1, 2008
24. http://www.emea.europa.eu/humandocs/ Humans/EPAR/novoseven/ novoseven.htm. Accessed May 1, 2008
25. Hedner U, Glazer S, Pingel K, et al: Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2:1193 (Pubitemid 18267024)
26. Hedner U: Recombinant coagulation factor VIIa: From the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26:363-366
27. O'Connell KA, Wood JJ, Wise RP, et al: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298 (Pubitemid 43112957)
28. Mathew P: The use of rFVIIa in nonhaemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost 2004; 92:738-746
29. Millar CG, Stringer MD, Sugarman I, et al: The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11:171-174 (Pubitemid 40468066)
30. Egan JR, Lammi A, Schell DN, et al: Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004; 30: 682-685 (Pubitemid 38530106)
31. Uhrig L, Blanot S, Baugnon T, et al: Use of recombinant activated factor VII in intractable bleeding during pediatric neurosurgical procedures. Pediatr Crit Care Med 2007; 8:576-579 (Pubitemid 350076465)
32. Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864 (Pubitemid 39620130)
33. Warren O, Mandal K, Hadjianastassiou V, et al: Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 2007; 83:707-714 (Pubitemid 46138055)
34. Lisman T, De Groot PG: Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1:1138-1139
35. Tobias JD, Groeper K, Berkenbosch JW: Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J 2003; 96:12-16 (Pubitemid 36207377)
36. Heller M, Lau W, Pazmino-Canizares J, et al: A comprehensive review of rFVIIa use in a tertiary care pediatric center. Pediatr Blood Cancer 2007; 50:1013-1017
37. Al Douri M, Shafi T, Al Khudairi D, et al: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(Suppl 1):S121-S127 (Pubitemid 30368715)
38. Aldouri M: The use of recombinant factor VIIa in controlling surgical bleeding in nonhaemophiliac patients. Pathophysiol Haemost Thromb 2002; 32(Suppl 1): 41-46 (Pubitemid 41296360)
39. Isbister J, Phillips L, Dunkley S, et al: Recombinant activated factor VII in critical bleeding: Experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008; 38:156-165 (Pubitemid 351271402)
40. Avci Z, Malbora B, Gokdemir M, et al: Successful use of recombinant factor VIIa (NovoSeven((R))) during cardiac surgery in a pediatric patient with congenital factor XI deficiency. Pediatr Cardiol 2008; 29:220-222
41. Brady KM, Easley RB, Tobias JD: Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Paediatr Anaesth 2006; 16:1042-1046 (Pubitemid 44401171)
42. Brose S, Sirbu H, Engel M, et al: Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation. Thorac Cardiovasc Surg 2005; 53:389-390 (Pubitemid 41783580)
43. Davis MC, Andersen NE, Johansson P, et al: Use of thromboelastograph and factor VII for the treatment of postoperative bleeding in a pediatric patient on ECMO after cardiac surgery. J Extra Corpor Technol 2006; 38: 165-167
44. Dominguez TE, Mitchell M, Friess SH, et al: Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005; 6:348-351 (Pubitemid 40724289)
45. Grizelj R, Vukovic J, Filipovic-Grcic B, et al: Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis 2006; 17:413-415 (Pubitemid 43941585)
46. Leibovitch L, Kenet G, Mazor K, et al: Recombinant activated factor VII for lifethreatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003; 4:444-446
47. López-Herce Cid J, Arriola Pereda G, Zunzunegui Martínez JL, et al: [Effectiveness of activated factor VII in postoperative bleeding after cardiac surgery with extracorporeal membrane oxygenation]. An Pediatr (Barc) 2005; 62:471-474
48. Milano Manso G, Rodriguez Amuedo F, Aragones Manzanero R, et al: [Use of activated factor VII in severe acute hemorrhage]. An Pediatr (Barc) 2005; 62:467-470
49. Pychynska-Pokorska M, Moll JJ, Krajewski W, et al: The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004; 5:246-250
50. Razon Y, Erez E, Vidne B, et al: Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 2005; 15:235-240 (Pubitemid 40364750)
51. Sheth S, Dimichele D, Lee M, et al: Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001; 7:227-232 (Pubitemid 32243808)
52. Skalski JH, Czapla J, Nadziakiewicz P, et al: [New possibilities in the postoperative measures to prevent bleeding in cardiac surgery. Will the recombinant activated factor VII improve surgical results?] Przegl Lek 2002; 59: 941-945
53. Tobias JD, Berkenbosch JW, Russo P: Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4:49-51
54. Tofil NM, Winkler MK, Watts RG, et al: The use of recombinant factor VIIa in a patient with Noonan syndrome and life-threatening bleeding. Pediatr Crit Care Med 2005; 6:352-354 (Pubitemid 40724290)
55. Tokunaga C, Hiramatsu Y, Horigome H, et al: Palliative open heart surgery in an infant with factor VII deficiency. Ann Thorac Surg 2003; 76:2093-2094 (Pubitemid 37510549)
56. Veldman A, Hoffman M, Ehrenforth S: New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003; 10:797-811 (Pubitemid 36443236)
57. Velik-Salchner C, Sergi C, Fries D, et al: Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg 2005; 101:924 (Pubitemid 41208540)
58. Verrijckt A, Proulx F, Morneau S, et al: Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2004; 127:1812-1813 (Pubitemid 38725466)
59. Wittenstein B, Ng C, Ravn H, et al: Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6:473-476 (Pubitemid 40980831)
60. Yilmaz BT, Alioglu B, Ozyurek E, et al: Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005; 26:843-845 (Pubitemid 43130184)
61. Reiter PD, Valuck RJ, Taylor RS: Evaluation of off-label recombinant activated factor VII for multiple indications in children. Clin Appl Thromb Hemost 2007; 13:233-240 (Pubitemid 47000549)
62. Tobias JD, Simsic JM, Weinstein S, et al: Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 2004; 19:270-273
63. Agarwal HS, Bennett JE, Churchwell KB, et al: Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007; 84:161-168
64. Ekert H, Brizard C, Eyers R, et al: Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006; 17:389-395
65. Pugliese F, Ruberto F, Summonti D, et al: Activated recombinant factor VII in orthotopic liver transplantation. Transplant Proc 2007; 39:1883-1885 (Pubitemid 47198825)
66. Hendriks HG, Meijer K, de Wolf JT, et al: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 2001; 71:402-405 (Pubitemid 32175976)
67. Friederich PW, Henny CP, Messelink EJ, et al: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double- blind placebo-controlled randomised trial. Lancet 2003; 361:201-205 (Pubitemid 36126219)
68. Diprose P, Herbertson MJ, O'Shaughnessy D, et al: Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebocontrolled pilot study. Br J Anaesth 2005; 95:596-602 (Pubitemid 41600019)
69. Trowbridge CC, Stammers AH, Ciccarelli N, et al: Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: A case report and brief review. J Extra Corpor Technol 2006; 38:254-259
70. Martinowitz U, Michaelson M: Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3:640-648 (Pubitemid 41647873)
71. Seremetis S: Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis 2003; 14(Suppl 1):S29-S30 (Pubitemid 36951879)
72. Shapiro AD: Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000; 26:413-419 (Pubitemid 30835882)
73. Villar A, Aronis S, Morfini M, et al: Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10:352-359 (Pubitemid 39077035)
74. Levy JH, Fingerhut A, Brott T, et al: Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: Review of safety profile. Transfusion 2006; 46:919-933 (Pubitemid 43800910)
75. Warren OJ, Darzi AW, Athanasiou T: Recombinant activated factor VII in cardiac surgery- first, do no harm. J Cardiothorac Surg 2007; 2:50
76. Swaminathan M, Shaw AD, Greenfield RA, et al: Fatal thrombosis after factor VII administration during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2008; 22:259-260
77. Chalwin RP, Tiruvoipati R, Peek GJ: Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 2008; 34:685-686
78. Riccabona M, Kuttnig-Haim M, Dacar D, et al: Venous thrombosis in and after extracorporeal membrane oxygenation: Detection and follow-up by color Doppler sonography. Eur Radiol 1997; 7:1383-1386 (Pubitemid 127538373)
79. Brown P, Brunnhuber K, Chalkidou K, et al: How to formulate research recommendations. BMJ 2006; 333:804-806
80. Welsby IJ, Ortel TL: Invited commentary. Ann Thorac Surg 2007; 84:168-169 (Pubitemid 46929108)
81. Shander A, Goodnough LT, Ratko T, et al: Consensus recommendations for the offlabel use of recombinant human factor VIIa (NovoSeven) therapy. Pharmacy Therapeutics 2005; 30:644-658 (Pubitemid 41808790)
82. Goodnough LT, Lublin DM, Zhang L, et al: Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-1331 (Pubitemid 39129245)